Insider · CIK 0001914883

Readnour Robin Shane

Reports to the SEC for 1 company · MENLO PARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001914883

Forms 4 and 5

Insider transactions

46 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-09	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−523 sh	$6.02	−$3,150.709	557,467
2026-09-09	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−585 sh	$6.02	−$3,524.216	624,765
2026-09-08	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−4,725 sh	$6.02	−$28.4K	557,990
2026-09-08	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−5,294 sh	$6.02	−$31.9K	625,350
2026-09-03	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−2,877 sh	$6.07	−$17.5K	562,715
2026-09-03	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−3,223 sh	$6.07	−$19.6K	630,644
2026-08-17	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−16.7K sh	$6.01	−$100K	565,592
2026-08-17	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−18.7K sh	$6.01	−$112K	633,867
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+20.7K sh	—	—	20,724
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20.7K sh	—	—	0
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+23.7K sh	—	—	23,742
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−23.7K sh	—	—	0
2026-02-20	ANTXAN2 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20.4K sh	—	—	20,400
2025-05-22	ANTXAN2 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+19.1K sh	—	—	19,111
2024-12-19	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+9,077 sh	—	—	9,077
2024-12-10	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+5,000 sh	$1.49	+$7,462	582,288
2024-12-10	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+5,000 sh	$1.49	+$7,467.5	652,573
2024-12-09	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+12.3K sh	$1.43	+$17.6K	577,288
2024-12-09	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+18.5K sh	$1.43	+$26.4K	647,573
2024-12-06	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+12.7K sh	$1.45	+$18.4K	564,999
2024-12-06	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+6,517 sh	$1.45	+$9,427.492	629,090
2024-11-27	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+25K sh	$1.42	+$35.4K	552,288
2024-11-27	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+25K sh	$1.42	+$35.4K	622,573
2024-11-26	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+12.5K sh	$1.39	+$17.4K	527,288
2024-11-26	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+12.5K sh	$1.39	+$17.4K	597,573
2024-11-20	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+25K sh	$1.16	+$29K	585,073
2024-11-20	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+25K sh	$1.15	+$28.9K	514,788
2024-11-19	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+75K sh	$1.03	+$77.5K	560,073
2024-11-19	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+75K sh	$1.04	+$77.7K	489,788
2024-06-19	ANTXAN2 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+64.5K sh	—	—	64,503
2024-01-12	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−706 sh	$21.92	−$15.5K	414,788
2024-01-12	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−719 sh	$21.91	−$15.8K	485,073
2024-01-10	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−1,869 sh	$21.93	−$41K	415,494
2024-01-10	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−1,800 sh	$21.92	−$39.5K	485,792
2023-06-07	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+23.7K sh	—	—	23,742
2022-05-12	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+20.7K sh	—	—	20,724
2022-03-29	ANTXAN2 Therapeutics, Inc.C Conversion	Director	CConversion	+285K sh	—	—	285,156
2022-03-29	ANTXAN2 Therapeutics, Inc.C Conversion	Director	CConversion	+333K sh	—	—	333,135
2022-03-29	ANTXAN2 Therapeutics, Inc.C Conversion	Director	CConversion	+61.5K sh	—	—	346,647
2022-03-29	ANTXAN2 Therapeutics, Inc.C Conversion	Director	CConversion	+71.8K sh	—	—	404,974
2022-03-29	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+70.7K sh	$15.00	+$1.06M	417,363
2022-03-29	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+82.6K sh	$15.00	+$1.24M	487,592
2022-03-29	ANTXAN2 Therapeutics, Inc. · Series A Convertible Preferred StockC Conversion	Director	CConversion	−285K sh	—	—	0
2022-03-29	ANTXAN2 Therapeutics, Inc. · Series A Convertible Preferred StockC Conversion	Director	CConversion	−333K sh	—	—	0
2022-03-29	ANTXAN2 Therapeutics, Inc. · Series B Convertible Preferred StockC Conversion	Director	CConversion	−61.5K sh	—	—	0
2022-03-29	ANTXAN2 Therapeutics, Inc. · Series B Convertible Preferred StockC Conversion	Director	CConversion	−71.8K sh	—	—	0

Recent filings

Accepted (ET)
Sep 114
Readnour Robin Shane0001193125-26-389545
SEC(opens sec.gov)
Sep 84
Readnour Robin Shane0001193125-26-385511
SEC(opens sec.gov)
Aug 194
Readnour Robin Shane0001193125-26-357225
SEC(opens sec.gov)
Mar 234
Readnour Robin Shane0001193125-26-120200
SEC(opens sec.gov)
Feb 234
Readnour Robin Shane0001193125-26-064103
SEC(opens sec.gov)
May 234
Readnour Robin Shane0000950170-25-077073
SEC(opens sec.gov)
Dec 234
Readnour Robin Shane0000950170-24-139792
SEC(opens sec.gov)
Dec 104
Readnour Robin Shane0000950170-24-135150
SEC(opens sec.gov)

Companies

AN2 Therapeutics, Inc.DirectorANTX

Address

C/O AN2 THERAPEUTICS, INC. 1300 EL CAMINO REAL, SUITE 100

MENLO PARK, CA, 94025